KRT88P and myeloid sarcoma: The aim of our study was to assess the risk of HBVr in patients with evidence of resolved HBV infection (anti-HBc positive/HBsAg negative/undetectable HBV-DNA) treated with monotherapy with anti-CD20 antibodies (rituximab or ocrelizumab) for MS or NMOSD, in the absence of antiviral prophylaxis.